C4 Therapeutics Advances Cemsidomide Trials with 2027 Data Readouts on Horizon — C4 Therapeutics, Inc.

Event summary

C4 Therapeutics' Phase 2 MOMENTUM trial for cemsidomide in relapsed refractory multiple myeloma is on track to complete enrollment by Q1 2027, with initial ORR data expected in the second half of 2027.
Phase 1b trial combining cemsidomide with elranatamab continues progress, with dose escalation updates expected in the second half of 2026 and full cohort data by mid-2027.
New Phase 1b combination trial with standard-of-care therapies (daratumumab and carfilzomib) set to initiate in the first half of 2027.
C4T secured $33.5 million through its ATM program and a $20 million upfront payment from Roche for a new collaboration on degrader-antibody conjugates (DAC).

The big picture

C4 Therapeutics is advancing its lead candidate, cemsidomide, through critical clinical trials aimed at establishing it as a backbone therapy for multiple myeloma. The company's strategic collaborations with Roche and others underscore the growing interest in targeted protein degradation (TPD) science, which could redefine treatment paradigms for difficult-to-treat cancers. With a strong cash position and upcoming data readouts, C4T is positioning itself to compete in an increasingly crowded oncology market.

What we're watching

Clinical Milestones: The pace at which cemsidomide's Phase 2 and combination trials deliver data in 2027 will determine its competitive positioning in the multiple myeloma space.
Financial Runway: Whether C4T’s $300.4 million cash position as of Q2 2026 will be sufficient to fund operations through 2028, given ongoing trial expenses and potential expansion costs.
Strategic Collaborations: How the Roche partnership on degrader-antibody conjugates (DAC) could expand C4T’s pipeline beyond cemsidomide and diversify its revenue streams.